Literature DB >> 19743866

Structure-activity relationships for substrate-based inhibitors of human complement factor B.

Gloria Ruiz-Gómez1, Junxian Lim, Maria A Halili, Giang T Le, Praveen K Madala, Giovanni Abbenante, David P Fairlie.   

Abstract

Human complement is a cascading network of plasma proteins important in immune defense, cooperatively effecting recognition, opsonization, destruction, and removal of pathogens and infected/damaged cells. Overstimulated or unregulated complement activation can result in immunoinflammatory diseases. Key serine proteases in this cascade are difficult to study due to their multiprotein composition, short lifetimes, formation on membranes, or serum circulation as inactive zymogens. Factor B is inactive at pH 7, but a catalytically active serine protease under alkaline conditions, enabling structure-activity relationship studies for 63 substrate-based peptide inhibitors with 4-7 residues and a C-terminal aldehyde. A potent factor B inhibitor was hexpeptide Ac-RLTbaLAR-H (IC(50) 250 nM, pH 9.5), which at pH 7 also blocked formation of membrane attack complex via the "alternative pathway" of complement activation and inhibited human complement mediated lysis of rabbit erythrocytes. Inhibitors of factor B may be valuable probes and drug leads for complement mediated immunity and disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19743866     DOI: 10.1021/jm900781m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes.

Authors:  Reik Löser; Jens Pietzsch
Journal:  Front Chem       Date:  2015-06-23       Impact factor: 5.221

2.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

3.  Exploring the Potential of Venom from Nasonia vitripennis as Therapeutic Agent with High-Throughput Screening Tools.

Authors:  Ellen L Danneels; Ellen M Formesyn; Dirk C de Graaf
Journal:  Toxins (Basel)       Date:  2015-06-03       Impact factor: 4.546

4.  Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.

Authors:  Anna Schubart; Karen Anderson; Nello Mainolfi; Holger Sellner; Takeru Ehara; Christopher M Adams; Aengus Mac Sweeney; Sha-Mei Liao; Maura Crowley; Amanda Littlewood-Evans; Sophie Sarret; Grazyna Wieczorek; Ludovic Perrot; Valérie Dubost; Thierry Flandre; Yuzhou Zhang; Richard J H Smith; Antonio M Risitano; Rajeshri G Karki; Chun Zhang; Eric Valeur; Finton Sirockin; Bernd Gerhartz; Paulus Erbel; Nicola Hughes; Thomas M Smith; Frederic Cumin; Upendra A Argikar; Börje Haraldsson; Muneto Mogi; Richard Sedrani; Christian Wiesmann; Bruce Jaffee; Jürgen Maibaum; Stefanie Flohr; Richard Harrison; Jörg Eder
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-29       Impact factor: 11.205

Review 5.  Complement, a target for therapy in inflammatory and degenerative diseases.

Authors:  B Paul Morgan; Claire L Harris
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 112.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.